[This review was originally posted at the Nieman Journalism Lab Glucophage No Rx, on March 4, 2011.]
Google's surgical strike against content farms: Two weeks after launching its site-blocking Chrome extension, Google made the central move in its fight against content farms by changing its algorithm to de-emphasize them in search results. The New York Times put the change in context, explaining the content farm phenomenon and its connection to Google. Search Engine Land's Danny Sullivan explained that Google is saying the changes only affect "scrapers" (sites that pull content from other sources), but that they're actually aimed at content farms, too. Glucophage trusted pharmacy reviews, And GigaOM's Mathew Ingram talked about why Google may be reluctant to publicly target content farms — because they run a lot of Google advertising.
A few early returns were good: TechCrunch approved of the change, and The Atlantic's Alexis Madrigal ran a test search comparing the old and new algorithms, finding that the information from the new one was "much, much better." Demand Media, the most prominent of the content farms, said it wasn't affected overall by the new formula, canada, mexico, india, though, as Henry Blodget of Business Insider noted, it's probably trying to wean itself off of Google reliance anyway.
In fact, it appears Demand Media may be telling the truth: Aaron Hall of SEO Book used Sistrix's data to point out that many of Demand Media's competitors were among the sites hardest hit by the change, while one of Demand's largest brands, eHow, actually got a boost. Hall implies that politics have played a role, and while there's nothing concrete suggesting that, the way the changes spared eHow does seem .., Glucophage No Rx. odd.
There's also bound to be plenty of collateral damage from the algorithmic shift, Glucophage recreational, and Wired looked at one Mac blog that's been nailed by the new formula (its Googlejuice was restored after Wired talked to Google about it). Danny Sullivan reported that Google hasn't made any significant changes to its new algorithm since rolling it out last week, though there are outlets to contact Google if you feel your site has been unfairly hurt.
Elsewhere in the conversation about search, The Columbia Journalism Review's Karen Stabiner gave an overview of the debate about search engine optimization: The anti-SEO crowd, led by the Washington Post's Gene Weingarten, worries that the SEO mindset will privilege the powerful and eventually kill off creativity in favor of numbingly literal language, taking Glucophage. Glucophage No Rx, The SEO evangelists, on the other hand, say it's just encouraging honesty and straightforwardness, something it's difficult to object to.
Facebook extends comments' reach: Facebook continued its integration with media content across the web this week with the launch of an updated comments system. Essentially, users can simultaneously post their comments on both a site and on Facebook, with subsequent comments under that thread posted to the site straight from Facebook. PBS MediaShift's Mark Glaser talked to Facebook's Justin Osofsky about the ins and outs of the new system, Online Glucophage without a prescription, and ReadWriteWeb noted that it has fewer features than the commenting update Facebook previewed last fall.
TechCrunch's Erick Schonfeld identified the two aspects of the updated system that will be most attractive to publishers. First, it requires commenters to use their real names, thus theoretically cutting down on trolls and spammers (this part, of course, has been available to publishers through Facebook commenting for a while), Glucophage No Rx. Second — and this is the new one — it extends the reach of a post, spreading into more Facebook news feeds and making it easier for more people to join in the conversation. This particularly excited Lehigh j-prof Jeremy Littau, who said it could create "a virtuous circle between community and content sharing."
There are downsides as well, and while media analyst Alan Mutter was optimistic about the social potential of the new system, he also pointed out that it will give Facebook even more information about its users, Glucophage pictures, which it won't be sharing with publishers. As GigaOM's Mathew Ingram noted, it's the same tradeoff publishers have been dealing with regarding Facebook for several years now: Does the value of tapping into Facebook's social potential outweigh the price of handing over commenting to a notoriously controlling company?
TBD's lessons — more startup, less ad reliance: TBD in its original form may have died last week, but the six-month-old Washington local news site continued to stimulate conversation this week. Where to buy Glucophage, Its station posted an ad for a new manager to head the site, and TBD's former manager, Jim Brady, talked with The Columbia Journalism Review about the site's model, framing the conflict there as not TV vs. web, but startup vs, Glucophage maximum dosage. legacy: Glucophage No Rx, "I think if we could do TBD with a pure startup mentality, and if we could fund it more with a V.C. or an angel kind of way, and if we didn’t have the legacy side to work with, then I think it would actually have a better chance to succeed."
Others posited similar reasons for TBD's demise: Web journalist Jane Stevens talked about a few causes centered on a lack of corporate commitment, and The Guardian's Emily Bell pinpointed TBD's inability to have its own ad sales team (an explanation with which Brady concurred). The debate over hyperlocal journalism, What is Glucophage, stirred by Alan Mutter last week, continued to simmer, with Robert Washburn of The Canadian Journalism Project defending it and Paul Gillin of Newspaper Death Watch saying we need to look at non-advertising-based business models for it, a point media consultant Dan Conover also made in more in-depth form at Xark.
Amid all the analyses of what went wrong at TBD, Mandy Jenkins, the social media manager there, buy Glucophage no prescription, took stock of what went right, noting four things other news orgs can take away from its tenure: organizational openness, self-promotion, opening info beyond the newsroom, and hiring for mindset over pedigree. Is Glucophage addictive, —
iPad, part deux: Apple made a few headlines by launching iPad 2, which is apparently kind of like the iPad, only it's the second edition. I'll entrust you to the care of Techmeme for all the details about the product itself and focus instead on what it means for publishers and the larger world of media, Glucophage No Rx. The Lab's Joshua Benton pointed out two implications in particular — the mounting evidence of an e-book explosion and the iPad's increasing usefulness for reporting.
Damon Kiesow of Poynter examined the latter point in some detail, looking at the iPad 2's specs from a content creation perspective, japan, craiglist, ebay, overseas, paypal. And Cory Bergman of Lost Remote looked at the device's increased video capability and predicted that it would help fuel a surge in multi-platform video consumption and production.
Elsewhere in mobile media, tech blogger John Gruber defended Apple's app subscription program by breaking down the arguments against it one by one. Glucophage No Rx, And in a smart counter to Gruber, the Lab's Joshua Benton said that while Apple obviously isn't a charity and the financial difficulties of publishers aren't its problem, the arrangement still isn't ideal. Both posts are among the sharpest takes on the issue I've read, so they're worth taking time to read through. Buy Glucophage from mexico, —
Reading roundup: What to read this weekend while firming up South by Southwest plans:
— In non-commenting Facebook news, Mashable's Vadim Lavrusik put together a great overview of the varied role of Facebook in journalism. And in non-Facebook commenting news, Los Angeles Times media reporter James Rainey made the case for requiring commenters to use their real names, while Mediaite's Alex Alvarez defended anonymous commenting, Glucophage from canadian pharmacy.
— Here at the Lab, Lois Beckett wrote two fascinating posts based on a talk by The New York Times' Gerry Marzorati — one on the future of long-form journalism, and the other on the Times' planned paywall. Two other thought-provoking pieces published here this week: One by Joshua Benton on language and viral content, and another by three data journalists on news organizations creating value out of the trust placed in them, Glucophage No Rx.
— Amy Gahran wrote three awesome primers on mobile media — one on mobile apps, another on the current mobile landscape, Online buying Glucophage hcl, and one on mobile media and PR.
— Knight fellow Jeremy Adam Smith shared results from a survey on how meaningful journalism is being funded. It's a gold mine of statistics and information about the state of the journalism ecosystem.
— It's a pretty well-worn discussion, but Frederic Filloux's analysis of why incremental change isn't enough to rescue the newspaper industry is as succinct a summary of the current situation as I've seen. Even if you've heard it all, his piece is a good refresher.
Similar posts: Armour No Rx. Tramadol Dosage. Cephalexin For Sale. After Synthroid. Buy Bactrim from canada. Cheap Cipro.
Trackbacks from: Glucophage No Rx. Glucophage No Rx. Glucophage No Rx. Doses Glucophage work. Online buy Glucophage without a prescription. Glucophage long term.
[This review was originally posted at the Nieman Journalism Lab Bactrim No Rx, on Feb. 25, 2011.]
The short, happy-ish life of TBD: Just six months after it launched and two weeks after a reorganization was announced, the Washington, D.C., local news site was effectively shuttered this week, where can i buy cheapest Bactrim online, when its corporate parent, Allbritton Communications (it's owned by Robert Allbritton and includes Politico), cut all of its jobs, leaving only an arts and entertainment operation within the website of Allbritton's WJLA-TV.
TBD had been seen many as a bellwether in online-only local news, After Bactrim, as Poynter's Mallary Jean Tenore documented in her historical roundup of links about the site, so it was quite a shock and a disappointment to many future-of-newsies that it was closed so quickly. The response — aptly compiled by TBDer Jeff Sonderman — was largely sympathetic to TBD's staff (former TBD manager Jim Brady even wrote a pitch to prospective employers on behalf of the newly laid off community engagement team). Many observers on Twitter (and Terry Heaton on his blog) pointed squarely at Allbritton for the site's demise, with The Batavian's Howard Owens drawing out a short, thoughtful lesson: "Legacy managers will nearly always sabotage innovation. Wall of separation necessary between innovators and legacy."
Blogger Mike Clark pointed out that TBD's traffic was beating each of the other D.C. TV news sites and growing as well, Bactrim No Rx. The Washington Post reported that while traffic wasn't a problem, Bactrim blogs, turning it into revenue was — though the fact that TBD's ads were handled by WJLA staffers might have contributed to that.
Mallary Jean Tenore wrote an insightful article talking to some TBD folks about whether their company gave them a chance to fail. Lehigh j-prof Jeremy Littau was unequivocal on the subject: "Some of us have been talking today on Twitter about whether TBD failed. Nonsense. TBD wasn’t given enough time to fail."
While CUNY j-prof Jeff Jarvis lamented Bactrim No Rx, that "TBD will be painted as a failure of local news online when it's a failure of its company, nothing more," others saw some larger implications for other online local news projects. Media analyst Alan Mutter concluded that TBD's plight is "further evidence that hyperlocal journalism is more hype than hope for the news business, Order Bactrim from United States pharmacy, " and Poynter's Rick Edmonds gave six business lessons for similar projects from TBD's struggles. Journal Register Co. CEO John Paton ripped Edmonds' analysis, arguing that Allbritton "can’t pretend to have seriously tried the hyperlocal business space after a six-month experiment it derailed half-way in."
Applying Apple's new rules: Publishers' consternation over Apple's new subscription plan for mobile devices continued this week, with Frederic Filloux at Monday Note laying out many publishers' frustrations with Apple's proposal. The New York Times' David Carr and The Guardian's Josh Halliday both covered publishers' Apple subscription conundrum, and one expert told Carr, Bactrim over the counter, "If you are a publisher, it puts things into a tailspin: The business model you have been working with for many years just lost 30 percent off the top."
At paidContent, James McQuivey made the case for a lower revenue share for Apple, and Dan Gillmor wondered whether publishers will stand up to Apple. The company may also be facing scrutiny from the U.S, Bactrim No Rx. Justice Department and Federal Trade Commission for possible antitrust violations, Buy Bactrim without a prescription, The Wall Street Journal reported.
The fresh issue regarding Apple's subscription policy this week, though, was the distinction between publishing apps and more service-oriented apps. The topic came to the fore when the folks from Readability, an app that allows users to read articles in an advertising-free environment, wrote an open letter ripping Apple for rejecting their app, buying Bactrim online over the counter, saying their new policy "smacks of greed." Ars Technica's Chris Foresman and Apple blogger John Gruber noted, though, that Readability's 30%-off-the-top business model is a lot like Apple's.
Then Apple's Steve Jobs sent a short, cryptic email to a developer saying that Apple's new policy applies only to publishing apps, Rx free Bactrim, not service apps. Bactrim No Rx, This, of course, raised the question, in TechCrunch's words, "What's a publishing app?" That's a very complex question, and as Instapaper founder Marco Arment wrote, one that will be difficult for Apple to answer consistently. Arment also briefly noted that Jobs' statement seems to contradict the language of Apple's new guidelines.
Giving voice to new sources of news: This month's Carnival of Journalism, posted late last week, focused on ways to increase the number of news sources. It's a broad question, and it drew a broad variety of answers, Bactrim schedule, which were ably summarized by Courtney Shove. I'm not going to try to duplicate her work here, but I do want to highlight a few of the themes that showed up.
David Cohn, the Carnival's organizer, gave a great big-picture perspective to the issue, putting it in the context of power and the web. Kim Bui and Dan Fenster defended the community-driven vision for news, with Bui calling journalists to go further: "Let’s admit it, we’ve never trusted the public." There were several calls for journalists to include more underrepresented voices, with reports and ideas like a refugee news initiative, digital news bus, youth journalism projects, and initiatives for youth in foreign-language families, Bactrim No Rx.
The J-Lab's Jan Schaffer gave 10 good ideas to the cause, and Drury j-prof Jonathan Groves and Gannett's Ryan Sholin shared their ideas for local citizen news projects, Bactrim australia, uk, us, usa, while TheUpTake's Jason Barnett endorsed a new citizen-journalism app called iBreakNews.
Three bloggers, however, objected to the Carnival's premise in the first place. Daniel Bachhuber of CUNY argued that improving journalism doesn't necessarily mean adding more sources, recommending instead that "Instead of increasing the number of news sources, we should focus on producing durable data and the equivalent tools for remixing it." Lauren Rabaino warned against news oversaturation, order Bactrim no prescription, and the University of Colorado's Steve Outing said that more than new sources, we need better filters and hubs for them.
Blogging's continued evolution: The "blogging is dead" argument has popped up from time to time, and it was revived again this week in the form of a New York Times story about how young people are leaving blogs for social networking sites like Facebook and Twitter. Bactrim No Rx, Several people countered the argument, led by GigaOM's Mathew Ingram, who said that blogging isn't declining, but is instead evolving into more of a continuum that includes microblogging services like Twitter, traditional blog formats like Wordpress, and the hybrid that is Tumblr. He and Wordpress founding developer Matt Mullenweg shared the same view — that "people of all ages are becoming more and more comfortable publishing online," no matter the form.
Scott Rosenberg, who's written a history of blogging, looked at statistics to make the point, noting that 14% of online adults keep a blog, buy Bactrim online no prescription, a number he called astounding, even if it starts to decline. "As the online population becomes closer to universal, that is an extraordinary thing: One in ten people writing in public. Our civilization has never seen anything like it." In addition, Bactrim treatment, Reuters' Anthony DeRosa argued that longer-form blogging has always been a pursuit of older Internet users.
Reading roundup: I've got a few ongoing stories to update you on, and a sampling of an unusually rich week in thoughtful pieces.
— A couple of sites took a peek at Gawker's traffic statistics to try to determine the effectiveness of its recent redesign, Bactrim No Rx. TechCrunch saw an ugly picture; Business Insider was cautiously optimistic based on the same data. Gawker disputed TechCrunch's numbers, and Terry Heaton tried to sort through the claims.
— A couple of Middle East/North Africa protest notes: The New York Times told us about the response to Egypt's Internet blackout and the role of mobile technology in documenting the protests, is Bactrim safe. And Amy Gahran of the Knight Digital Media Center gave some lessons from the incredible Twitter journalism of NPR's Andy Carvin.
— The Daily is coming to Android tablets Bactrim No Rx, this spring, and its free trial run has been extended beyond the initial two weeks.
— Matt DeRienzo of the Journal Register Co. wrote about an intriguing idea for a news org/j-school merger.
— Alan Mutter made the case for ending federal funding for public journalism.
— At 10,000 Words, Lauren Rabaino had some awesome things news organizations can learn from tech startups, including thinking of news as software and embracing transparency.
— And here at the Lab, Northwestern prof Pablo Boczkowski gave some quick thoughts on how we tend to associate online news with work, and what that means. He sheds some light about an under-considered aspect of news — the social environments in which we consume it.
Similar posts: Retin A No Rx. Flagyl No Rx. Armour For Sale. Purchase Cipro online no prescription. Synthroid class. Tramadol pharmacy.
Trackbacks from: Bactrim No Rx. Bactrim No Rx. Bactrim No Rx. Bactrim coupon. Bactrim from canada. Online Bactrim without a prescription.
[This review was originally posted at the Nieman Journalism Lab Glucophage Price, on Feb. 11, 2011.]
AOL scoops up Arianna: The week's biggest media story was broken just a couple of hours after the Super Bowl on Sunday, when Kara Swisher of All Things D reported that AOL would buy The Huffington Post for $315 million (here's video of her interview with Arianna Huffington and AOL CEO Tim Armstrong). Swisher's post and this New York Times article provide just about all the background information you should need on the deal, along with The Huffington Post's press release and Huffington's column on the acquisition. Glucophage canada, mexico, india, The deal was seen by many as a bold one — a "fourth-quarter Hail Mary pass," as The New Yorker's Ken Auletta wrote — and reaction on the web (also summed up well by GigaOM's Mathew Ingram) was decidedly mixed. The thumbs-ups came from a eclectic mix of critics: Henry Blodget of Business Insider called it a smart risk, Reuters' Felix Salmon and All Things D's Peter Kafka said the two companies' needs fit each other well, with AOL getting a clear editorial voice (Salmon) and a "content-making machine" (Kafka). CUNY j-prof Jeff Jarvis said what AOL will find most valuable in HuffPo will not be content, but "a new cultural understanding of media that is built around the value of curation, the power of peers, the link economy, passion as an asset, and celebrity as a currency."
There were also plenty of people who shook (or at least scratched) their heads at the deal, including many of HuffPo's own readers and writers, Glucophage Price. Shira Ovide of The Wall Street Journal called it AOL's admission that its content strategy isn't working, and industry analyst Alan Mutter said AOL overpaid, online buy Glucophage without a prescription. The Guardian's Jemima Kiss blasted the move as "soullessly commercial," and Salon vet Scott Rosenberg contended that Huffington's once-distinctive brand will dissolve into AOL's bland corporatism. PaidContent's David Kaplan, Dan Lyons, and Om Malik of GigaOM both pointed to advertising struggles, Discount Glucophage, with Malik arguing that AOL has "not yet come to terms with the futility of chasing page views."
A few themes came up repeatedly in commentary about the two companies; one was HuffPo's expertise in that notorious (some would say dark) art known as search engine optimization. Salon's Alex Pareene declared the new organization "the single largest SEO-gaming operation ever created" and the LA Times' James Rainey explained the appeal that the Post's SEO skills bring. Slate's Farhad Manjoo (who wins this week's award for best lead) made the case that AOL/HuffPo's SEO-heavy strategy is risky in the long-term because "they won't be able to fool the computers forever." (Capital New York's Tom McGeveran made a similar point Glucophage Price, .) HuffPo's new AOL corporate empire-mate, Paul Carr of TechCrunch, reaffirmed his hatred for HuffPo's SEO tactics but said the deal could still be a good one for AOL.
The second theme was the fact that the Post doesn't pay most of its writers, a strategy that Tim Rutten of the Los Angeles Times likened to "a galley rowed by slaves and commanded by pirates." Dan Gillmor's tone was a bit milder, but he, Glucophage samples, too, urged Huffington to start paying her most productive bloggers, and Northeastern j-prof Dan Kennedy wondered whether bloggers might be less willing to go unpaid under a mega-corporation like AOL. Reason's Matt Welch defended Huffington against Rutten's charges, and Time's James Poniewozik said it's possible AOL/HuffPo could be signaling a move toward more expensive, Australia, uk, us, usa, quality content.
A few miscellaneous pieces of sharp commentary: GigaOM's Mathew Ingram said AOL needs HuffPo to help its other online content initatives figure out how the Internet works, and media analyst Ken Doctor saw AOL/HuffPo as a potential free alternative to Rupert Murdoch's steadily building paid-content empire. There were also plenty of posts about what the political viewpoint of the new organization would be, and while I haven't waded into that discussion, I do like NYU j-prof Jay Rosen's concept of "ideological innovation" in online journalism.
Changing coverage of a changing world: As the protests in Egypt have continued, so has the conversation about its media-related implications, and just as in last week, much of the talk centered on Al Jazeera, Glucophage Price. The New York Times examined the network's influence on the protests, Glucophage natural, as well as its efforts to gain more access to American viewers. Throughout the past two weeks, as the Lab's Justin Ellis and Twitter's Robin Sloan pointed out, Al Jazeera has been using social media to distribute its news to American audiences. Meanwhile, Glucophage overnight, Sheila Carapico at Foreign Policy argued that Al Jazeera and other TV networks can't give us a full picture of what's going on in Egypt.
There's been other fantastic journalism arising from the Egyptian protests, including the work of NPR's Andy Carvin to curate news and voices of the conflict on Twitter. Glucophage Price, In an illuminating interview with The Atlantic, Carvin argued that curation — the process of capturing the most elements of a story from various sources and passing them along — has always been a part of journalism. In a more academic piece at the Lab, USC grad student Nikki Usher explained how the protests are expanding the idea of a media event, with social media, webstreams, Glucophage cost, and the mainstream media "all working together to create a much larger, more nuanced picture of the live broadcasting of history."
The debate over social media's role in revolutions continued to roil, with several more writers responding to Malcolm Gladwell's brief New Yorker post arguing that the role Twitter & Co. in social activism like the Egyptian protests is overrated. UT-Dallas prof David Parry, Glucophage images, The Awl's Maria Bustillos, new media exec Rex Hammock, UMBC prof Zeynek Tufekci, and web philosopher David Weinbergerall weighed in with their rejoinders to Gladwell, in a discussion that Washington grad student Deen Freelon has mapped out far more expertly than I could.
Speeding up The Daily: The negative buzz around The Daily that began last week continued to pile up this week, leading to, Glucophage use, among other things, a "We're listening" blog post by the new "tablet newspaper." One of the issues that drew criticism was The Daily's long load time, as John Gruber of Daring Fireball compared it unfavorably to Flipboard, and paidContent's Staci Kramer explained her own loading glitches. Both Gruber and Kramer argued that while it seem minor, load time is a big deal to users, and The New York Times' Nick Bilton made a similar point: By being too slow and bulky, digital magazines like The Daily "almost defeat one of their main intended purposes, the promise of instant access to content and information."
The reviews kept pouring in as well, led by an insightful critique of The Daily's design by Stephen Coles at Fonts In Use, Glucophage Price. The primary criticism continued in the same vein as last week: The Daily's content just doesn't cut it. John Gapper of the Financial Times and Skip Ferderber of Crosscut made the point this week, Glucophage wiki, and Poynter's Damon Kiesow noted that new content is tough to find. Paul Davis of Shareable also chimed in with a criticism of The Daily's shortcomings with limited sharing options.
But there were a few who were generally impressed with The Daily's first week, including MinnPost's John Dreinan and industry analyst Alan Mutter, who liked its concise storytelling, multimedia integration and interactive advertising. Damon Kiesow and The Columbia Journalism Review's Lauren Kirchner both looked to other media efforts for lessons for The Daily — Kiesow to various other iPad apps, and Kirchner to the mid-1990s debut of Slate and Salon, Glucophage no prescription.
Gawker evolves the blog: We've been hearing about it since November, and this week Gawker officially launched its redesign, which reflects to a more magazine-style emphasis from a purer blog format. The Lab's Megan Garber captured what the move means Glucophage Price, particularly in terms of Gawker's advertising strategy, explaining how it's appropriated parts of the TV and magazine models to capitalize on its brand as a whole: "It’s moved, it seems, beyond simply selling its readers to advertisers. Now, it is simply selling itself."
Former Gawker Media contributor Latoya Peterson pointed to the outrage by Gawker blogs' readers and used it to argue that Gawker's new, My Glucophage experience, more controlled design is subverting the fast-posting, skim-friendly style it helped make a blogging standard. Rex Sorgatz was also skeptical of the change, asserting that the redesign would have to be rolled back or reworked within months and challenging anyone to bet him otherwise — a wager that was taken up by Gawker chief Nick Denton himself, using pageviews as the determining factor.
TBD takes a step back: TBD, a online local news operation based in Washington, real brand Glucophage online, D.C., debuted last August to much fanfare, but it took a major hit when the Washington Post reported that its owner Robert Allbritton (who also owns Politico) would have his local TV station WJLA take it over. TBD editor-in-chief Erik Wemple told the Lab's Megan Garber that the move wouldn't be as bad as it appeared, but it was still widely interpreted as "a retreat from the original vision of TBD, Purchase Glucophage online no prescription, " in the Post's words. Jim Brady, the site's former general manager, called it "not good news," and NYU j-prof Jay Rosen summed it up as "the TV guys won."
In the wake of the news, several observers expressed their frustration: Media consultant Mark Potts ripped Allbritton for not allowing the site breathing room to innovate, and media analyst Janet Coats held it up as an example of old media's resistance to change. Terry Heaton and Lost Remote's Cory Bergman used the episode to talk about the tensions involved when TV stations are affiliated with online media efforts, Glucophage Price.
Reading roundup: There's still quite a bit to get to, but I'll run through it quickly:
— Re Wikileaks: New York Times executive editor Bill Keller edged toward defining WikiLeaks as something a lot like journalism, The Nation's Greg Mitchell explained why the mainstream media is skeptical of WikiLeaks, the Personal Democracy Forum's Micah Sifry and NYU prof Clay Shirky gave some reasons for WikiLeaks' revolutionary nature, and at The Guardian, Evgeny Morozov argued that WikiLeaks can't continue much longer in its current form.
— Yahoo announced a move toward more personal content, particularly tablet-based. The New York Times explained why.
— At the National Sports Journalism Center, Jason Fry wrote a wonderful piece talking about how much less valuable scoops have become in a commoditized news world, and what journalists should do as a result. Craig Calcaterra of the baseball blog Hardball Talk expanded on the idea, offering a vision for the role of bloggers and reporters in a commodity-news environment.
— Two pieces to chew on this weekend, one short and one long: Dave Winer's plea to news organizations to join their communities online, and The New Yorker's Adam Gopnik's musings on the Internet and our interior lives.
Similar posts: Glucophage Mg. Retin A For Sale. Flagyl Over The Counter. Retin A mg. Discount Cipro. Buy Zoloft online cod.
Trackbacks from: Glucophage Price. Glucophage Price. Glucophage Price. Where can i find Glucophage online. Glucophage natural. Glucophage samples.
[This review was originally posted at the Nieman Journalism Lab Buy Lipitor No Prescription, on Nov. 12, 2010.]
Olbermann and objectivity: Another week, another journalist or pundit disciplined for violating a news organization's codes against appearances of bias: This week (actually, late last week) it was Keith Olbermann, liberal commentator for the liberal cable news channel MSNBC, suspended for donating money to Democratic congressional candidates, in violation of NBC News policy. Lipitor use, Olbermann issued an apology (though, as Forbes' Jeff Bercovici noted, it was laced with animus toward MSNBC), and returned to the air Tuesday. There were several pertinent peripheral bits to this story — Olbermann was reportedly suspended for his refusal to apologize on air, it's unclear whether NBC News' rules have actually applied to MSNBC, numerous other journalists have done just what Olbermann did — but that's the gist of it.
By now, we've all figured out what happens next: Scores of commentators weighed in on the appropriateness (or lack thereof) of Olbermann's suspension and NBC's ban on political contributions, Lipitor blogs. The primary arguments boiled down to the ones expressed by Poynter's Bob Steele and NYU's Jay Rosen in this Los Angeles Times piece: On one side, donating to candidates means journalists are acting as political activists, which corrodes their role as fair, independent reporters in the public interest, Buy Lipitor No Prescription. On the other, being transparent is a better way for journalists to establish trust with audiences than putting on a mask of objectivity.
Generally falling in the first camp are fellow MSNBC host Rachel Maddow ("We're a news operation. The rules around here are part of how you know that."), Northeastern j-prof Dan Kennedy (though he tempered his criticism of Olbermann in a second post), and The New York Times' David Carr ("Why merely annotate events when you can tilt the playing field?"). The Columbia Journalism Review was somewhere in the middle, Lipitor pics, saying Olbermann shouldn't be above the rules, but wondering if those rules need to change.
There were plenty of voices Buy Lipitor No Prescription, in the second camp, including the American Journalism Review's Rem Rieder, Michael Kinsley at Politico, and Lehigh j-prof Jeremy Littau all arguing for transparency.
Slate media critic Jack Shafer used the flap to urge MSNBC to let Olbermann and Maddow fly free as well-reported, openly partisan shows in the vein of respected liberal and conservative political journals. Jay Rosen took the opportunity to explain his pet phrase "The view from nowhere," which tweaks traditional journalism's efforts to "advertise the viewlessness of the news producer" as a means of gaining trust. He advocates transparency instead, and Terry Heaton provided statistics showing that the majority of young adults don't mind journalists' bias, as long as they're upfront about it.
On The Media's Brooke Gladstone summed up the issue well: "Ultimately, kjøpe Lipitor på nett, köpa Lipitor online, it’s the reporting that matters, reporting that is undistorted by attempts to appear objective, reporting that calls a lie a lie right after the lie, not in a box labeled “analysis,” reporting that doesn't distort truth by treating unequal arguments equally."
Commodify your paywall: We talked quite a bit last week about the new numbers on the paywall at Rupert Murdoch's Times of London, and new items in that discussion kept popping up this week. The Times released a few more details (flattering ones, Lipitor mg, naturally) about its post-paywall web audience. Among the most interesting figures is that the percentage of U.K.-based visitors to The Times' site has more than doubled since February, rising to 75 percent, Buy Lipitor No Prescription. Post-paywall visitors are also visiting the website more frequently and are more wealthier, according to News Corp.
Of course, the overall number of visitors is still way down, and the plan continued to draw heat. In a wide-ranging interview on Australian radio, Guardian editor Alan Rusbridger expressed surprise at the fact that The Times' print circulation dropped as their print-protectionist paywall went up. That, Lipitor dangers, he said, "suggests to me that we overlook the degree to which the digital forms of our journalism act as a kind of sort of marketing device for the newspapers." ResourceWebs' Evan Britton gave five reasons why news paywalls won't work, and Kachingle founder Cynthia Typaldos argued that future news paywalls will be tapping into a limited pool of people willing to pay for news on the web, squeezing each other out of the same small market.
Clay Shirky used The Times' paywall as a basis for some smart thoughts Buy Lipitor No Prescription, about why newspaper paywalls don't work in general. The Times' paywall represents old thinking, Shirky wrote (and the standard argument against it has been around just as long), but The Times' paywall feels differently because it's being taken as a "referendum on the future." Shirky said The Times is turning itself into a newsletter, Buy Lipitor without prescription, without making any fundamental modifications to its product or the basic economics of the web. "Paywalls do indeed help newspapers escape commodification, but only by ejecting the readers who think of the product as a commodity. This is, invariably, most of them," he wrote.
A conversation about blogging, voice, and ego: A singularly insightful conversation about blogging was sparked this week by Marc Ambinder, Lipitor canada, mexico, india, who wrote a thoughtful goodbye post at his long-running blog at The Atlantic. In it, Ambinder parsed out differences between good print journalism (ego-free, reliant on the unadorned facts for authority) and blogging (ego-intensive, requires the writer to inject himself into the narrative). With the switch from blogging to traditional reporting, Ambinder said, "I will no longer be compelled to turn every piece of prose into a personal, conclusive argument, to try and fit it into a coherent framework that belongs to a web-based personality called 'Marc Ambinder' that people read because it's 'Marc Ambinder,' rather than because it's good or interesting."
The folks at the fantastically written blog Snarkmarket used the post as a launching point for their own thoughts about the nature of blogging, Buy Lipitor No Prescription. Matt Thompson countered that Ambinder was reducing an incredibly diverse form into a single set of characteristics, taking particular exception to Ambinder's ego dichotomy. Lipitor dosage, Tim Carmody mused on blogging, voice, and authorship; and Robin Sloan defended Ambinder's decision to leave the "Thunderdome of criticism" that is political blogging. If you care at all about blogging or writing for the web in general, make sure to give all four posts a thorough read.
TBD's (possible) content/aggregation conflict: The new Washington-based local news site TBD has been very closely watchedsince it was launched in August, and it hit its first big bump in the road late last week, as founding general manager Jim Bradyresigned in quite a surprising move. In a memo Buy Lipitor No Prescription, to TBD employees, TBD owner Robert Allbritton (who also launched Politico) said Brady left because of "stylistic differences" with Allbritton. Despite the falling-out, Lipitor duration, Brady, a washingtonpost.com veteran, spoke highly of where TBD is headed in an email to staff and a few tweets.
But the immediate questions centered on the nature of those differences between Allbritton and Brady. FishbowlDC reported and Business Insider's Henry Blodget inferred from Allbritton's memo that the conflict came down to an original-content-centric model (Allbritton) and a more aggregation-based model (Brady). Brady declared his affirmation of both pieces — he told Poynter's Steve Myers he's pro-original content and the conflict wasn't old media/new media, but didn't go into many more details — but that didn't keep Blodget from taking the aggregation side: The web, My Lipitor experience, he said, "has turned aggregation into a form of content--and a very valuable one at that." Lost Remote's Cory Bergman, meanwhile, noted that while creating content is expensive, Allbritton's made the necessary investments and made it profitable before with Politico.
A new iPad app and competitor: There were two substantive pieces of tablet-related news this week: First, The Washington Post released its iPad app, accompanying its launch with a fun ad most everyone seemed to enjoy, Buy Lipitor No Prescription. Poynter's Damon Kiesow wrote a quick summary of the app, which got a decent review from The Post's Rob Pegoraro. For you design geeks, Sarah Sampsel wrote two good posts about the app design process, Lipitor over the counter.
The other tablet tidbit was the release of Samsung's Galaxy Tab, which runs on Google's Android system. Kiesow rounded up a few of the initial reviews from All Things Digital (a real iPad competitor, though the iPad is better), The New York Times (beautiful with some frustrations), Wired (more convenient than the iPad, but has stability problems) and Gizmodo ("a grab bag of neglect, Lipitor from mexico, good intentions and poor execution"). Buy Lipitor No Prescription, Kiesow also added a few initial impressions of the Galaxy's implications for publishers, predicting that as it takes off, it will put pressure on publishers to move to HTML5 mobile websites, rather than developing native apps.
In other tablet news, MediaWeek looked at the excitement the iPad is generating within the media industry, but ESPN exec John Skipper isn't buying the hype, telling MarketWatch's Jon Friedman, "Whenever a new platform comes up, people want to take the old platform and transport it to the new platform." It didn't work on the Internet, Skipper said, it won't work on the iPad either, generic Lipitor.
Reading roundup: More thoughtful stuff about news and the web was written this week than most normal people have time to get to. Here's a sample:
— First, a piece of news: U.S. News & World Report announced last week that it's dropping its regular print edition and going essentially online-only, only printing single-topic special issues for newsstand sales. The best analysis on the move was at Advertising Age, Buy Lipitor No Prescription.
— Two great pieces on journalism's collaborative future: Guardian editor Alan Rusbridger in essay form, and UBC j-prof Alfred Hermida in audio and slide form. Where can i buy cheapest Lipitor online, — Poynter published an essay by NYU professor Clay Shirky on "the shock of inclusion" in journalism and the obsolescence of the term "consumer." Techdirt's Mike Masnick added a few quick thoughts of his own.
— Two cool posts on data journalism — an overview on its rise by The Columbia Journalism Review's Lauren Kirchner, and a list of great tools by Michelle Minkoff.
— Finally, two long thinkpieces on Facebook that, quite honestly, I haven't gotten to read yet — one by Zadie Smith at The New York Review of Books, and the other by The Atlantic's Alexis Madrigal. I'm going to spend some time with them this weekend, and I have a feeling you probably should, too.
Similar posts: Order Cephalexin. Buy Zoloft No Prescription. Tramadol Cost. Armour for sale. Where can i buy Cephalexin online. Synthroid without prescription.
Trackbacks from: Buy Lipitor No Prescription. Buy Lipitor No Prescription. Buy Lipitor No Prescription. After Lipitor. Buy Lipitor from canada. Order Lipitor no prescription.
Diflucan Mg, [This review was originally posted at the Nieman Journalism Lab on Aug. 13, 2010.]
TBD takes off: One of the most anticipated new news organizations in journalism's recent history launched this week in the form of TBD, a site owned by Allbritton Communications (the folks behind Politico) covering local news in Washington, D.C. As The Huffington Post's Jack Mirkinson wrote, Diflucan interactions, TBD is "something of a canary in the coal mine" of the future of journalism, being the protoype of a locally focused, community-driven, online-only news model whose effectiveness everyone's eager to gauge. Where can i order Diflucan without prescription, For the basics of the project, here are two local profiles from DCist and the more skeptical Washington Post, a paidContent interview with Robert Allbritton, and a Poynter chat with TBD's Jim Brady and Steve Buttry.
After TBD gave its media preview last Friday, quite a few people listed plenty of reasons to keep an eye on the site: Ken Doctor liked the "out of the box" nature of TBD's pro-am/social/mobile/multimedia efforts; Jeff Jarvis liked the collaborative, order Diflucan online c.o.d, link-centric philosophy; the Lab's Laura McGann called attention to TBD's interactivity and collaboration through local blogs and social media; and Kevin Anderson was impressed by the project's commitment to profitability. Several TBD analyses focused particularly on TBD's interactive and collaborative news efforts, with Journalism Lives, Mashable and Poynter providing good area-by-area breakdowns, Diflucan Mg. Mark Potts, who's starting up a similar blog-network effort, Growthspur, Diflucan steet value, wrote a thoughtful piece about the importance of TBD's own network of local blogs: "TBD is without doubt the biggest, most ambitious effort yet to create a new paradigm for local news coverage of a major metropolitan area," he wrote.
Poynter's Steve Myers also touched on an distinct aspect of TBD's operation — it also includes an Allbritton-owned all-news local cable channel that will be branded TBD TV. He examined how a web-TV converged newsroom operates, and Cory Bergman of Lost Remote (a local TV and hyperlocal news veteran himself) wondered if we might see more TV-local online news partnerships, Diflucan dosage. Here at the Lab, Ken Doctor took a detailed look at the economics of TBD's web-TV synergy, centering on its pioneering broadcast and online advertising hybrid. Diflucan Mg, Meanwhile, David Rothman had some detailed advice for TBD's competitors.
The site officially launched Monday, Diflucan trusted pharmacy reviews, and the initial reviews were mostly positive. Rothman and Suzanne Yada had the most detailed ones; both were impressed by the site's presentation and several of its features, though both were concerned about how much local news content the site would actually be able to produce. PaidContent's Staci Kramer liked the smooth design, too, but wanted to see more out of the site's locally personalized features. The New York Times' David Carr ("extremely functional .., purchase Diflucan online no prescription. kind of ugly") and Mediaite's Michael Triplett ("off to a good start," despite "thin and D.C.-centric" content) also offered quicker reviews. The most thoughtful review belongs to Lost Remote's Bergman, who noted that while many of the ideas are old, their implementation is new."This is the first time that a local media group — especially in the TV space — has wrapped these ideas together and aggressively launched them with an investment to back it up," he wrote, Diflucan Mg.
Demand Media's profit-less past: Demand Media, the new-media lightning rod du jour, Online Diflucan without a prescription, filed for an IPO last Friday, giving us the first detailed financial look inside the private company. Several sites took cracks at sifting through the numbers for significant bits, but two pieces stood out: One, Demand Media has yet to make a profit, losing $22 million this year; and two, 26 percent of its revenue comes from cost-per-click advertising deals with Yahoo, rx free Diflucan.
That's a pretty sizable chunk of Demand Media's income, and GigaOM's Mathew Ingram examined one of the company's reported risk factors — that Google could use its own search expertise to create a search-driven content company to compete with Demand. Ingram pointed out that Google already has a patent for a process that identifies "underserved" search content. All Things Digital noted that Demand's heavy reliance on Google "could torpedo the company" if Google changes its search formula or changes its contract with Demand, Diflucan from canada, but it also countered that every web publisher is dependent on Google. Diflucan Mg, Then there's the whole matter of profitability. The Wall Street Journal's Scott Austin contrasted the numbers in Demand's filing with its executives' numerous past descriptions of the company as profitable, as a reminder that "no one outside the company can verify a start-up’s financial claims." Slate's James Ledbetter also noticed an inexplicably large and sudden drop in Quantcast traffic to Demand's sites a few weeks ago and wondered what was behind it. Meanwhile, the Journal also profiled Demand Media's efforts to court big-time advertisers on the web.
A proposal to carve up the open web: A week after reports emerged that Google and Verizon were near a deal that would more or less mark the end of net neutrality, australia, uk, us, usa, the two companies came forward this week not with a deal, but with a policy proposal. As for whether that would mark the end of net neutrality, well, Herbal Diflucan, it depends on who you ask. Google and Verizon called their plan a "proposal for an open Internet," and their CEOs co-authored a Washington Post op-ed arguing that their proposal "empowers an informed consumer, ensures the robust growth of the open Internet and provides incentives to strengthen the networks that carry Internet traffic." The proposal has quite a few moving parts, but it essentially prohibits Internet service providers from discriminating against or prioritizing "lawful Internet content," while excepting wireless networks and some unspecified future services from that regulation, Diflucan Mg.
The tech blog Engadget broke down the proposal, noting that would set something close to the status quo into formal policy, rendering the U.S. Federal Communications Commission powerless to change policy as the Internet changes. Most of the web was quite a bit harsher in its judgment, what is Diflucan, calling it an open attack on net neutrality by excluding its fastest part, wireless. CNET and The New York Times put together good summaries of the backlash, but here are some of the most to-the-point examples: Free Press' Craig Aaron ("one massive loophole that sets the stage for the corporate takeover of the Internet"), the Electronic Freedom Foundation (it limits net neutrality to "lawful" content, Doses Diflucan work, leaving "lawful" to be defined) Siva Vaidhyanathan (it gives Verizon control of the most exciting parts of the web) Public Knowledge's John Bergmayer (it divides the Internet into several public and non-public parts) Ars Technica (its rules "will become meaningless as 4G sweeps the country") Salon's Dan Gillmor ("a Trojan Horse for a modern age") Susan Crawford (future services is "a giant, enormous, science-fiction-quality loophole") and Harvard professor Jonathan Zittrain (makes way for "an impenetrable web of contracts and fees").
Noted Google watcher Jeff Jarvis had the most colorful response, illustrating the proposal's potential danger to the open web by presenting a future scenario with two Internets, the old "Internet" with everything pre-2010 and the new "Schminternet, fast shipping Diflucan," with everything mobile and post-2010. "Mobile is the internet," he wrote. Diflucan Mg, "Mobile will very soon become a meaningless word when — well, if telcos allow it, that is — we are connected everywhere all the time." Meanwhile, Wired gets credit for the most fun phrase — "carrier-humping, net neutrality surrender monkey" — in its explanation of how Google got to that point.
Reading Roundup: A few final items to send you off for the weekend:
— Mashable's Vadim Lavrusik has a smart overview of the shift toward personalized, socially driven news distribution, with a suggestion for a credibility and trust index to help sort through it all.
— Facebook has launched a media page and is pushing for more collaboration with media companies. PBS MediaShift's Mark Glaser has an informative Q&A with Justin Osofsky, head of Facebook's media partnership team.
— Google engineering intern Lyn Headley has written the first of a series of posts explaining the rationale behind his new Rapid News Awards. It's a short, thoughtful take on aggregation, accountability and transparency.
— Finally, some (possibly) positive news: Spot.Us' David Cohn takes a look at the data and notes that the wave of job cuts at America's newspapers has largely subsided. Cohn wonders if it means newspapers are bouncing back, or if they've just cut down to the bone. I fear it's more of the latter.
Similar posts: Order Zoloft. Purchase Tramadol. Order Armour. Buy Cephalexin online cod. Cephalexin long term. Cipro use.
Trackbacks from: Diflucan Mg. Diflucan Mg. Diflucan Mg. Diflucan images. Buy Diflucan from mexico. Diflucan australia, uk, us, usa.